Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation

被引:101
作者
Frei, Christopher R. [1 ,2 ]
Wiederhold, Nathan P. [1 ,2 ]
Burgess, David S. [1 ,2 ]
机构
[1] Univ Texas Austin, Ctr Advancement Res & Educ Infect Dis, Austin, TX 78712 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA
关键词
Pseudomonas; Acinetobacter; beta-lactam antibiotics; stochastic; computer modelling;
D O I
10.1093/jac/dkm536
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: This study describes a comprehensive programme designed to develop pharmacokinetic-pharmacodynamic (PK-PD) breakpoints for numerous antimicrobial classes against key Gram-negative aerobic bacteria. Methods: A 10 000 subject Monte Carlo simulation was constructed for 13 antimicrobials (21 dosing regimens). Published pharmacokinetic data and protein binding were varied according to log-normal and uniform distributions. MICs were fixed at single values from 0.03 to 64 mg/L. The PK-PD susceptible breakpoint was defined as the MIC at which the probability of target attainment was >= 90%. PK-PD, CLSI and European Committee on Antimicrobial Susceptibility Testing breakpoints were applied to MICs from the 2005 worldwide Meropenem Yearly Susceptibility Test Information Collection database to evaluate the impact of breakpoint discrepancies. Results: PK-PD breakpoints were within one dilution of the CLSI and European breakpoints for all antimicrobials tested-with a few exceptions. When discrepancies were noted, the PK-PD breakpoint was lower than the CLSI breakpoint [ceftriaxone (0.5 versus 8 mg/L), ertapenem (0.25 versus 2 mg/L), ciprofloxacin (0.125 versus 1 mg/L) and levofloxacin (0.25-0.5 versus 2 mg/L)] and higher than the European breakpoint [ceftazidime (4-8 versus 1 mg/L), aztreonam (4-8 versus 1 mg/L), although ciprofloxacin was an exception to this pattern (0.125 versus 0.5-1 mg/L)]. For Enterobacteriaceae, breakpoint discrepancies resulted in modest (<= 10%) differences in the percentages susceptible. In contrast, large (> 15%) discrepancies were noted for Pseudomonas aeruginosa and Acinetobacter baumannii. Conclusions: Breakpoint agreement exists for imipenem, meropenem and the aminoglycosides. In contrast, discrepancies exist for piperacillin/tazobactam, cephalosporins, ertapenem, aztreonam and the fluoroquinolones. These discrepancies are most pronounced for P. aeruginosa and A. baumannii.
引用
收藏
页码:621 / 628
页数:8
相关论文
共 44 条
[1]   Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore [J].
Ambrose, Paul G. ;
Bhavnani, Sujata M. ;
Rubino, Christopher M. ;
Louie, Arnold ;
Gumbo, Tawanda ;
Forrest, Alan ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) :79-86
[2]   Monte Carlo simulation in the evaluation of susceptibility breakpoints: Predicting the future - Insights from the society of infectious diseases pharmacists [J].
Ambrose, PG .
PHARMACOTHERAPY, 2006, 26 (01) :129-134
[3]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[4]   Animal model pharmacokinetics and pharmacodynamics: a critical review [J].
Andes, D ;
Craig, WA .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :261-268
[5]   PHARMACOKINETICS OF CEFEPIME AFTER SINGLE AND MULTIPLE INTRAVENOUS ADMINISTRATIONS IN HEALTHY-SUBJECTS [J].
BARBHAIYA, RH ;
FORGUE, ST ;
GLEASON, CR ;
KNUPP, CA ;
PITTMAN, KA ;
WEIDLER, DJ ;
MOVAHHED, H ;
TENNEY, J ;
MARTIN, RR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) :552-557
[6]  
BHAVNANI SM, 47 INT C ANT AG CHEM
[7]   Comparison of β-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics [J].
Burgess, DS ;
Frei, CR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (05) :893-898
[8]   Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses [J].
Chien, SC ;
Rogge, MC ;
Gisclon, LG ;
Curtin, C ;
Wong, F ;
Natarajan, J ;
Williams, RR ;
Fowler, CL ;
Cheung, WK ;
Chow, AT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2256-2260
[9]   Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers [J].
Chien, SC ;
Wong, FA ;
Fowler, CL ;
Callery-D'Amico, SV ;
Williams, RR ;
Nayak, R ;
Chow, AT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :885-888
[10]  
Clinical and Laboratory Standards Institute, 2007, PERF STAND ANT SUSC